Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

EP: 1.The Incidence of Prostate Cancer and Risk of Progression in Black Men

EP: 2.Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men

EP: 3.Representation of Black men with mHSPC in clinical trials

EP: 4.The current treatment landscape of mHSPC

EP: 5.Efficacy outcomes in Black patients from the ARANOTE trial

EP: 6.Safety data on Black patients from ARANOTE

EP: 7.Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients

Now Viewing

EP: 8.Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

EP: 9.Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions

EP: 10.The importance of studying efficacy and safety of treatment in Black patients with mHSPC

EP: 11.Improving diversity in future clinical trials for mHSPC

EP: 12.Remaining unmet needs in diverse populations with mHSPC

Overall Survival Considerations

Key Themes:

• ARANOTE’s overall survival data are still maturing.
• ARASENS data show a promising trend for survival benefit.
• Competing risks and care access issues complicate survival analysis.
• Treatment completion challenges may impact long-term outcomes.

Key Points for Physicians:

• Although definitive overall survival data are pending, trends appear promising.
• Consider social determinants and access issues that may impact long-term outcomes.
• Address potential barriers to treatment completion.
• Monitor for mature survival data as they become available.

Notable Insights: The complexity of survival analysis highlights the importance of considering factors beyond drug efficacy, particularly access to care and treatment completion, which may disproportionately affect Black patients.

Clinical Significance: Early survival trends appear promising but require longer follow-up and consideration of the broader context of care delivery and social determinants that influence outcomes.